Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data

@inproceedings{Yamashita2013ModelingOR,
  title={Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data},
  author={Fumiyoshi Yamashita and Yukako Sasa and Shuya Yoshida and Akihiro Hisaka and Yoshiyuki Asai and Hiroaki Kitano and Mitsuru Hashida and Hiroshi Suzuki},
  booktitle={PloS one},
  year={2013}
}
Induction of cytochrome P450 3A4 (CYP3A4) expression is often implicated in clinically relevant drug-drug interactions (DDI), as metabolism catalyzed by this enzyme is the dominant route of elimination for many drugs. Although several DDI models have been proposed, none have comprehensively considered the effects of enzyme transcription/translation dynamics on induction-based DDI. Rifampicin is a well-known CYP3A4 inducer, and is commonly used as a positive control for evaluating the CYP3A4… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Determination of a Degradation Constant for CYP3A4 by Direct Suppression of mRNA in a Novel Human Hepatocyte Model, HepatoPac.

Drug metabolism and disposition: the biological fate of chemicals • 2015
View 6 Excerpts
Highly Influenced

ADME Processes in Pharmaceutical Sciences

Springer International Publishing • 2018

References

Publications referenced by this paper.
Showing 1-10 of 69 references

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2007
View 2 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…